Cardiff Oncology, Inc.

CRDF · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$45,431-$41,441-$38,704-$28,291
Dep. & Amort.$404$398$236$451
Deferred Tax$0$0$0$1,323
Stock-Based Comp.$4,760$4,509$4,256$3,234
Change in WC$3,172$6,568-$380-$1,789
Other Non-Cash-$598-$921$772$2,032
Operating Cash Flow-$37,693-$30,887-$33,820-$23,040
Investing Activities
PP&E Inv.-$80-$582-$892-$205
Net Acquisitions$0$0-$114$205
Inv. Purchases-$23,563-$70,084-$91,233-$174,385
Inv. Sales/Matur.$37,371$106,861$130,274$43,142
Other Inv. Act.$0$0$114-$205
Investing Cash Flow$13,728$36,195$38,149-$131,448
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$53,407$0$75$34,187
Stock Repurch.$0$0$0$0
Dividends Paid$0$0-$414-$24
Other Fin. Act.$373$0$414$1,287
Financing Cash Flow$53,780$0$75$35,450
Forex Effect$0$0$0$0
Net Chg. in Cash$29,815$5,308$4,404-$119,038
Supplemental Information
Beg. Cash$21,655$16,347$11,943$130,981
End Cash$51,470$21,655$16,347$11,943
Free Cash Flow-$37,773-$31,469-$34,712-$23,245